Research programme: duchenne muscular dystrophy therapeutics - Daiichi Sankyo/Orphan Disease Treatment Institute
Alternative Names: ENA® oligonucleotidesLatest Information Update: 16 Jul 2016
At a glance
- Originator Daiichi Sankyo Company; Orphan Disease Treatment Institute
- Developer Daiichi Sankyo Company
- Class Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Duchenne muscular dystrophy in Japan (Parenteral)
- 14 Feb 2013 Early research in Duchenne muscular dystrophy in Japan (Parenteral)